- Home
- EFSC vs MESO Comparison
EFSC vs MESO Comparison
Compare EFSC & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EFSC | MESO |
|---|---|---|
| Founded | 1988 | 2004 |
| Country | United States | Australia |
| Employees | N/A | 108 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 1996 | 2005 |
Fundamental Metrics
Financial Performance| Metric | EFSC | MESO |
|---|---|---|
| Price | $59.34 | $14.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $66.33 | N/A |
| AVG Volume (30 Days) | ★ 227.1K | 156.1K |
| Earning Date | 04-22-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.36% | N/A |
| EPS Growth | ★ 9.94 | N/A |
| EPS | ★ 2.39 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.22 | $629.74 |
| Revenue Next Year | $3.77 | $30.65 |
| P/E Ratio | $24.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $51.18 | $13.05 |
| 52 Week High | $68.73 | $21.50 |
Technical Indicators
Market Signals| Indicator | EFSC | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 28.96 | 42.64 |
| Support Level | $59.26 | $14.18 |
| Resistance Level | $59.54 | $16.06 |
| Average True Range (ATR) | 1.12 | 0.42 |
| MACD | -0.24 | -0.08 |
| Stochastic Oscillator | 3.27 | 30.73 |
Price Performance
Historical ComparisonAbout EFSC Enterprise Financial Services Corporation
Enterprise Financial Services Corporation is a financial holding company. It offers banking and wealth management services to individuals and business customers located in Arizona, California, Florida, Kansas, Missouri, Nevada, and New Mexico, in addition to loan and deposit production offices throughout the United States. The company offers a broad range of business and personal banking services including wealth management services. Its Lending services include commercial and industrial, commercial real estate, real estate construction and development, residential real estate and consumer loans.
About MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.